Le Roux Carel W, Koroleva Anna, Larsen Sara, Foot Ellie
Diabetes Complications Research Centre, School of Medicine, Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland.
Market Access, Novo Nordisk, Novo Nordisk A/S, Søborg, Denmark.
Clin Obes. 2025 Feb;15(1):e12704. doi: 10.1111/cob.12704. Epub 2024 Oct 28.
A cross-sectional, online survey was conducted in the United Kingdom, France, Germany, and the United States (14 November-22 December 2022) to investigate preferences for anti-obesity medication (AOM) among people with obesity (PwO) and healthcare providers (HCPs). Eligibility: Adult PwO who self-defined their body type as overweight/obese, were trying to lose weight and had BMI ≥30.0 or 27.0-29.9 kg/m with ≥1 obesity-related complication; HCPs had to see ≥30 PwO in a typical month and be a decision-maker regarding their weight loss. The survey included 2500 PwO and 500 HCPs. Exercise (96%) and diet (90%) were the most common weight management methods; AOM use was low (8%). Key barriers to use of prescribed AOMs among PwO were not wanting to take AOM (34%), side effects concerns (33%), and not trusting AOM (26%). Most HCPs (79%) had prescribed/recommended AOMs. Efficacy was the most common reason for preferring one of the shown product profiles among PwO (60%) and HCPs (86%); improving cardiovascular risk was also important to 95% of HCPs when deciding which AOM to prescribe. AOM preference is largely driven by efficacy. Increasing knowledge could help to address barriers to AOM use and improve outcomes for PwO.
2022年11月14日至12月22日，在英国、法国、德国和美国开展了一项横断面在线调查，以调查肥胖者（PwO）和医疗服务提供者（HCPs）对减肥药（AOM）的偏好。入选标准：自我定义身体类型为超重/肥胖、正在尝试减肥且BMI≥30.0或27.0 - 29.9kg/m²且伴有≥1种肥胖相关并发症的成年PwO；HCPs在一个典型月内必须诊治≥30名PwO，且是其减肥决策的制定者。该调查纳入了2500名PwO和500名HCPs。运动（96%）和饮食（90%）是最常见的体重管理方法；减肥药的使用率较低（8%）。PwO中使用处方减肥药的主要障碍是不想服用减肥药（34%）、担心副作用（33%）以及不信任减肥药（26%）。大多数HCPs（79%）曾开具/推荐过减肥药。疗效是PwO（60%）和HCPs（86%）中选择所示产品简介之一的最常见原因；在决定开具哪种减肥药时，改善心血管风险对95%的HCPs也很重要。减肥药的偏好很大程度上由疗效驱动。增加知识有助于消除减肥药使用的障碍，并改善PwO的治疗效果。
